Australia's AdAlta rises on FDA granting orphan drug status to lead cancer therapy
BUZZ-Australia's AdAlta rises on FDA granting orphan drug status to lead cancer therapy ** Shares of Australia's AdAlta 1AD.AX rise as much as 20% to A$0.003
** Stock set for its second consecutive session of gains if trend holds
** Biotech firm says US FDA Orphan Drug Designation for EW-001 in mesothelioma assigned
** EW-001 is a CAR-T cell therapy being developed to treat malignant mesothelioma, a rare and aggressive cancer often linked to asbestos exposure
** Near 3.8 million shares change hands, 1.0x the 30-day average volume
** Stock has fallen 16.7% YTD, including session moves
(Reporting by Roshan Thomas in Bengaluru)
Recent news on Adalta
See all newsAustralia's AdAlta rises on FDA granting orphan drug status to lead cancer therapy
Brief: Adalta Says FDA Assigns Orphan Drug Designation For EW-001 In Mesothelioma To Adalta
Australia's AdAlta surges as partner lands up to $120 million cell therapy deal
Brief: Adalta Says Oribiotech Deal Validates Adalta Manufacturing Strategy
Brief: Adalta Says Regulatory Advisors Appointed For BZDS1901